Table 1.

Baseline characteristics and comorbidities of patients within the two subgroups.

	Dexamethasone (n = 113)		No dexamethasone (n = 65)
Baseline characteristics	Median	IQR	Median	IQR	P-value
Age (years)	66	59–78	64	56–76	0.313
BMI (kg/m2)	29	26–33	27	25–31	0.099
	%	N	%	N	P -value
Male sex	72.6	82	72.3	47	0.970
Diabetes mellitus	36.3	41	29.2	19	0.411
Arterial hypertension	66.4	75	53.8	35	0.111
History of smoking	29.2	33	21.5	14	0.294
Coronary artery disease	20.4	23	16.9	11	0.693
Peripheral artery disease	6.2	7	6.2	4	0.991
Atrial fibrillation	17.7	20	10.8	7	0.279
Heart failure	15.0	17	9.2	6	0.355
Obstructive lung disease	23.0	26	13.8	9	0.172
Structural lung disease	8.0	9	4.6	3	0.540
Malignancy	7.1	8	9.2	6	0.773
History of thromboembolism	12.4	14	6.2	4	0.209
Therapeutic anticoagulation during ICU stay	74.3	84	49.2	32	0.001

BMI, body mass index; IQR, interquartile range.